Human stem cell response to layered zirconium phosphate.
Nakamura J., Endo K., Sugawara-Narutaki A., Ohtsuki C.
Laboratory Study, published in RSC Adv (2020) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- RSC Adv (2020)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 35517070
- PMCID
- PMC9057008
- DOI
- 10.1039/d0ra04924g
- Citations
- 2
Abstract (original English)
This study aims to evaluate the in vitro cytocompatibility of layered zirconium phosphate (ZP) and its derivative material that was organically modified using glycerophosphate (ZGP). The ZP and ZGP particles were prepared via a reflux method in an aqueous solution containing phosphoric acid. The field emission scanning electron microscopy showed the prepared samples were fine particles with 70-100 nm diameter. X-ray diffraction and Raman spectrometry indicated the presence of a layered crystal structure. The interlayer distance of ZP was estimated to be 0.76 nm from the 002 diffraction. Modification of ZP with β-glycerophosphate, lead to expansion of the interlayer distance of 0.85 nm. Grazing incidence X-ray diffraction and Raman spectrometry showed that the crystal structures of ZP and ZGP were maintained even after the samples were coated onto polyethylene (PE) substrates via hot pressing. The water droplet contact angles on the PE substrates coated with the ZP and ZGP particles (ZP/PE and ZGP/PE) were 2 ∼ 6° lesser than that on the uncoated PE substrate. After human adipose-derived stem cells (hASCs) were cultured on the substrates, 2.5-3.5 times higher numbers of adhered cells were observed on the substrates coated with ZP and ZGP than on the uncoated PE substrates and 1.1-1.6 times higher than on the substrate coated with hydroxyapatite particles (HAp/PE). Increasing cell
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.